Cerepro - instructions for use, doses, side effects, contraindications

Composition:1 ml of the solution contains 250 mg of glycerylphosphorylcholine hydrate (in terms of 100% glycerylphosphorylcholine) (choline alfoscerate) as the active ingredient; excipients - water for injection up to 1 ml.

Description:Transparent colorless liquid.

Pharmacotherapeutic group:Nootropic agent.

ATX: & nbsp

N.07.A.X.02 Choline alfoscerate

Pharmacodynamics:Central cholinostimulator, which contains 40.5% of metabolically protected choline (metabolic protection contributes to the release of choline in the brain). Upon ingestion, it is cleaved under the action of enzymes on choline and glycerophosphate: choline participates in the biosynthesis of acetylcholine, one of the main neurotransmitter mediators; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) neuronal membrane. Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation.Increases the linear velocity of blood flow on the side of traumatic brain injury, contributes to the normalization of spatiotemporal characteristics of spontaneous bioelectrical activity of the brain; has a positive effect on the cognitive and behavioral responses of patients with cerebral vascular diseases.

It improves brain functions, affecting the pathogenetic factors of the involutionary psychoorganic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity. Dose-dependent stimulation of acetylcholine release; participating in the synthesis of phosphatidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, receptor function. Does not affect the reproductive cycle and does not have a teratogenic and mutagenic effect.

Pharmacokinetics:Absorption - 88%, easily penetrates the blood-brain barrier (with oral intake, the concentration in the brain is 45% of that in the plasma). It is mainly excreted in the lungs, in the form of carbon dioxide (85%), as well as by the kidneys and through the intestine (15%).

Indications:

- acute and recovery periods of craniocerebral trauma (incl.with a disturbance of consciousness, a coma);

- disorders of cerebral circulation according to the ischemic type (acute and recovery period) and hemorrhagic type (recovery period), with focal hemispheric symptoms or symptoms of brain stem damage;

- psychoorganic syndrome on the background of degenerative and involuntary changes in the brain and the consequences of cerebrovascular insufficiency;

- cognitive disorders (impaired mental function, memory, confusion, disorientation, decreased motivation, initiative and ability to concentrate), including with dementia and encephalopathy.

- senile pseudomelanchia, changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest.

Contraindications:

Hypersensitivity, pregnancy, breastfeeding.

Carefully:With caution: (due to the lack of data on the efficacy and safety of the drug in children and adolescents under 18 years)

Dosing and Administration:Intramuscularly in a dose of 1000 mg (1 ampoule) per day or intravenously (slowly) from 1000 mg to 3000 mg per day.With intravenous administration, the contents of one ampoule (4 ml) are diluted in 50 ml of physiological saline, the infusion rate is 60-80 drops per minute. Duration of treatment is 10-15 days, but if necessary, the treatment can be continued until the appearance of positive dynamics and the ability to switch to taking capsules.

Precautions for use

If there is nausea after taking the drug should reduce the dose.

Side effects:Allergic reactions, nausea (due to dopaminergic activation).

Overdose:Symptoms: dyspeptic disorders. Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.

Interaction:Not found.

Effect on the ability to drive transp. cf. and fur:Cerepro does not affect the speed of psychomotor reactions.

Form release / dosage:Solution for intravenous and intramuscular injection.

Packaging:By 3, 5 or 10 ampoules per pack or box of cardboard with partitions or liners made of paper. 3 or 5 ampoules per contour cell pack. For 1 or 2 contour squares in a box or a pack of cardboard. In each box or pack, the instructions for use and the opener for opening ampoules or the ampoule scarifier are put.When using ampoules with incisions or a fracture ring, a scarifier ampoule or a knife for opening ampoules is not inserted.

Storage conditions:At a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:4 years. Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LS-000476

Date of registration:02.06.2010

The owner of the registration certificate:VEROPHARM SA VEROPHARM SA Russia

Manufacturer: & nbsp

VEROPHARM SA Russia

Information update date: & nbsp26.09.2015

Illustrated instructions

Instructions

Cerepro® (Cerepro®)